JPMorgan upgrades Gilead and Pfizer, sees upside potential in healthcare sector
From Nasdaq: 2025-04-01 08:15:00
Wall Street analysts recently upgraded Gilead Sciences Inc. (NASDAQ: GILD), signaling renewed confidence in the healthcare sector amid market volatility. J.P. Morgan’s endorsement of Gilead’s fundamentals and technical strength has attracted major institutions, with the potential for a 16.1% upside to a new 52-week high near $130.
Pfizer Inc. (NYSE: PFE) offers a value-based, defensive opportunity with improving earnings projections and a 6.8% annual dividend yield. Analysts see a potential 25.9% upside from current levels, with a consensus price target of $31.92. Pfizer provides stability and modest growth amidst market volatility.
Hims & Hers Health Inc. (NYSE: HIMS) presents a contrarian growth play in the healthcare space, backed by improving fundamentals and growing institutional interest. With the stock trading at just 38% of its 52-week high, a recovery to $73 per share would represent a massive 147% upside. This growth-focused name could benefit from broader sector strength. 1. In a new study, researchers have found that eating a diet high in ultra-processed foods may increase the risk of developing inflammatory bowel disease (IBD). The study looked at over 116,000 participants and found a significant association between ultra-processed food intake and IBD.
2. The United Nations has reported that the global food prices have reached a 10-year high in November, with a 3.9% increase from the previous month. The rise in prices is attributed to supply chain disruptions and increased demand for food products.
3. A new survey conducted by the American Psychological Association has revealed that 78% of adults in the United States are feeling increased stress levels due to the ongoing COVID-19 pandemic. The survey also found that financial worries and concerns about the future are major sources of stress for many Americans.
4. The World Health Organization has warned that the Omicron variant of COVID-19 is spreading at an unprecedented rate and could lead to a surge in cases globally. The variant has been detected in over 89 countries and is believed to be more transmissible than previous variants.
5. In a groundbreaking discovery, scientists have identified a new type of cell in the human brain that may play a key role in neurodegenerative diseases like Alzheimer’s. The discovery could lead to new treatments and therapies for these devastating conditions.
Read more at Nasdaq:: 2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating